Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

Circulation. 2024 Jul 23;150(4):343-345. doi: 10.1161/CIRCULATIONAHA.124.069382. Epub 2024 May 11.

¹ Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.L.N., B.L.C., S.D.S., M.V.).
² George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., V.P., H.J.L.H.).
³ Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.).
⁴ National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Australia (M.J.).
⁵ Department of Clinical Pharmacy and Pharmacology, University of Groningen, Netherlands (H.J.L.H.).
⁶ Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.W.M.).
⁷ British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.).

No abstract available

Keywords: chronic kidney disease; heart failure.

Publication types